{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:18:23Z","timestamp":1788985103510,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We assess whether the COVID-19 pandemic was associated with increased adoption of ultra-hypofractionated (UH) radiotherapy (RT) in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort study of women with early-stage breast cancer across the United States using medical claims of a 5% sample of Fee-for-Service Medicare beneficiaries with newly diagnosed breast cancer treated with lumpectomy and post-surgery radiotherapy between 2018 and 2021. The primary endpoint was the beneficiary\u2019s fractionation schedule for the first course of radiotherapy treatment. The schedule was classified as: UH (\u22645 fractions), hypofractionated (6 to 10 fractions), moderate (11 to 21 fractions), and conventional (22+ fractions).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 4086 patients, 2504 (61%) were in the pre-COVID group, and 1582 (39%) were in the post-COVID group. Both groups were similar in age, health status, and geographical location. The UH rate increased 5-fold from 1.7% in the pre-COVID group to 8.4% in the post-COVID group (adj diff=6.8\u00a0pp,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001). Conversely, the conventional RT rate dropped from 23.2% of the pre-COVID to 16.4% of the post-COVID group (adj diff=6.8\u00a0pp,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A significant increase in 5-fraction UH and a decrease in conventional RT treatment were observed among Medicare breast cancer patients in the 18 months following the COVID-19 pandemic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coc.0000000000001373","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:02:52Z","timestamp":1788984172000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Ultra-Hypofractionated Radiotherapy in Breast Cancer Before and After COVID-19"],"prefix":"10.1097","author":[{"given":"Andre A.","family":"Konski","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine"},{"name":"Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YoonKyung","family":"Chung","sequence":"additional","affiliation":[{"name":"Harvey L. Neiman Health Policy Institute, Reston, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Mei","family":"Liu","sequence":"additional","affiliation":[{"name":"Harvey L. Neiman Health Policy Institute, Reston, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Y.","family":"Rula","sequence":"additional","affiliation":[{"name":"Harvey L. Neiman Health Policy Institute, Reston, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"R1-20260909","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-20260909","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardization of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomized controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"R3-20260909","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00317","article-title":"Three-year outcomes with hypofractionated versus conventionally fractionated whole-breast irradiation: results of a randomized, noninferiority clinical trial","volume":"36","author":"Shaitelman","year":"2018","journal-title":"J Clin Oncol"},{"key":"R4-20260909","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J Clin Oncol"},{"key":"R5-20260909","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.20.01024","article-title":"Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China","volume":"38","author":"Wang","year":"2020","journal-title":"J Clin Oncol"},{"key":"R6-20260909","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J Clin Oncol"},{"key":"R7-20260909","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal-tissue effects results from a multicentre, non-inferiority, randomized, phase 3 trial","volume":"395","author":"Murray","year":"2020","journal-title":"Lancet"},{"key":"R8-20260909","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","article-title":"Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline","volume":"8","author":"Smith","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"R9-20260909","doi-asserted-by":"crossref","first-page":"324","DOI":"10.6004\/jnccn.2016.0037","article-title":"Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Gradishar","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"R10-20260909","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/j.ijrobp.2020.07.2458","article-title":"Patterns of care of radiotherapy use in the treatment of breast cancer: why aren\u2019t we choosing wisely?","volume":"108","author":"Konski","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R11-20260909","doi-asserted-by":"crossref","first-page":"101487","DOI":"10.1016\/j.adro.2024.101487","article-title":"Geographic and physician-level variation in the use of hypofractionated radiation therapy for breast cancer in the US: a cross-classified multilevel analysis","volume":"9","author":"Sun","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"R12-20260909","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2020.09.004","article-title":"Trends in use of hypofractionated whole breast radiation in breast cancer: an analysis of the National Cancer Database","volume":"109","author":"Woodward","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-20260909","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/COC.0000000000000332","article-title":"Evaluating candidacy for hypofractionated radiation therapy, accelerated partial breast irradiation, and endocrine therapy after breast conserving surgery: a Surveillance Epidemiology And End Results (SEER) analysis","volume":"41","author":"Manyam","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"R14-20260909","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/tbj.13051","article-title":"Most patients are eligible for an alternative to conventional whole breast irradiation for early-stage breast cancer: a National Cancer Database analysis","volume":"24","author":"Balagamwala","year":"2018","journal-title":"Breast J"},{"key":"R15-20260909","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10549-020-05644-z","article-title":"Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium","volume":"181","author":"Dietz","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"R16-20260909","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1016\/j.clon.2022.05.019","article-title":"Change in the use of fractionation in radiotherapy used for early breast cancer at the start of the COVID-19 pandemic: a population-based cohort study of older women in England and Wales","volume":"34","author":"Gannon","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R17-20260909","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/COC.0000000000001167","article-title":"Impact of consensus guidelines, clinical trials, and COVID-19 on fractionation practices for node-negative intact breast cancer","volume":"48","author":"Cruttenden","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"R18-20260909","doi-asserted-by":"crossref","first-page":"e079089","DOI":"10.1136\/bmj-2023-079089","article-title":"Randomized controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis","volume":"386","author":"Lee","year":"2024","journal-title":"Brit Med J"},{"key":"R19-20260909","doi-asserted-by":"crossref","first-page":"104593","DOI":"10.1016\/j.canrad.2025.104593","article-title":"Moderate versus ultra-hypofractionated locoregional breast radiotherapy: results of a retrospective study during the COVID-19 era","volume":"29","author":"Rivera","year":"2025","journal-title":"Cancer Radiother"},{"key":"R20-20260909","doi-asserted-by":"crossref","first-page":"e2300010","DOI":"10.1200\/GO.23.00010","article-title":"Looking back: international practice patterns in breast radiation oncology from a case-based survey across 54 countries during the first surge of the COVID-19 pandemic","volume":"9","author":"Oladeru","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"R22-20260909","doi-asserted-by":"crossref","first-page":"e695","DOI":"10.1093\/cid\/ciaa1419","article-title":"Risk factors for coronavirus disease 2019 (COVID-19)-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system","volume":"72","author":"Ko","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R23-20260909","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijrobp.2023.11.043","article-title":"Trends in utilization and medicare spending on short-course radiation therapy for breast and prostate cancer: an episode-based analysis from 2015 to 2019","volume":"119","author":"Patel","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/COC.0000000000001373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:02:55Z","timestamp":1788984175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/COC.0000000000001373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000001373","relation":{},"ISSN":["0277-3732","1537-453X"],"issn-type":[{"value":"0277-3732","type":"print"},{"value":"1537-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"2026-08-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}